Cargando…
The clinical outcome of recurrent sacral chordoma with further surgical treatment
Case series. To analyze the clinical results and related factors of further surgical treatment for recurrent sacral chordomas. Chordomas are rare primary malignant tumors with a high recurrence rate. The treatment of recurrent tumors is difficult and controversial. Contamination by previous operatio...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314672/ https://www.ncbi.nlm.nih.gov/pubmed/30593146 http://dx.doi.org/10.1097/MD.0000000000013730 |
_version_ | 1783384140275515392 |
---|---|
author | Yang, Yongkun Li, Yuan Liu, Weifeng Xu, Hairong Niu, Xiaohui |
author_facet | Yang, Yongkun Li, Yuan Liu, Weifeng Xu, Hairong Niu, Xiaohui |
author_sort | Yang, Yongkun |
collection | PubMed |
description | Case series. To analyze the clinical results and related factors of further surgical treatment for recurrent sacral chordomas. Chordomas are rare primary malignant tumors with a high recurrence rate. The treatment of recurrent tumors is difficult and controversial. Contamination by previous operations and disturbed local anatomical structures may increase the risk of reoperation. Most previous studies have focused on the primary tumor; there are very few reports on the clinical diagnosis, treatment, and prognosis of recurrent sacral chordomas. Thirty-four patients with recurrent sacral chordomas from 1979 to 2014 were included in this study. The patients comprised 25 men and 9 women with an average age of 50.7 (24–75) years. The average time until recurrence was 19.4 (4–51) months postoperatively, and 85.3% of the recurrent tumors were located in bone. The patients had an average of 1.2 (1–3) recurrences before further operations were performed in our hospital. The mean maximum tumor diameter was 8.1 (4.6–12.0) cm. Thirty-one patients underwent further tumor resection in our hospital. The postoperative recurrence, metastasis, and survival results were followed and analyzed. The mean follow-up after surgical treatment of recurrence was 49.6 (12–144) months. Nine patients (37.5%) developed recurrence again after an average of 26.7 months. The 3-year and 5-year recurrence-free survival rate was 69.4% and 63.1%, respectively. Multivariate analysis showed that the tumor level within the sacrum (P = .001) and the surgical margin (P = .001) were significant recurrence-related factors. Four patients (16.7%) developed lung metastasis. Eighteen patients were alive at last follow-up. The 5-year and 10-year survival rate after surgical treatment of recurrence was 67.3% and 53.9%, respectively. Most recurrent tumors are located in bone, and a safe osteotomy margin is important. The surgical margin is the only controllable factor of further tumor recurrence. Some patients with recurrence achieve long survival and obtain a clinical benefit from repeated operations if complete resection is achieved. |
format | Online Article Text |
id | pubmed-6314672 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-63146722019-01-14 The clinical outcome of recurrent sacral chordoma with further surgical treatment Yang, Yongkun Li, Yuan Liu, Weifeng Xu, Hairong Niu, Xiaohui Medicine (Baltimore) Research Article Case series. To analyze the clinical results and related factors of further surgical treatment for recurrent sacral chordomas. Chordomas are rare primary malignant tumors with a high recurrence rate. The treatment of recurrent tumors is difficult and controversial. Contamination by previous operations and disturbed local anatomical structures may increase the risk of reoperation. Most previous studies have focused on the primary tumor; there are very few reports on the clinical diagnosis, treatment, and prognosis of recurrent sacral chordomas. Thirty-four patients with recurrent sacral chordomas from 1979 to 2014 were included in this study. The patients comprised 25 men and 9 women with an average age of 50.7 (24–75) years. The average time until recurrence was 19.4 (4–51) months postoperatively, and 85.3% of the recurrent tumors were located in bone. The patients had an average of 1.2 (1–3) recurrences before further operations were performed in our hospital. The mean maximum tumor diameter was 8.1 (4.6–12.0) cm. Thirty-one patients underwent further tumor resection in our hospital. The postoperative recurrence, metastasis, and survival results were followed and analyzed. The mean follow-up after surgical treatment of recurrence was 49.6 (12–144) months. Nine patients (37.5%) developed recurrence again after an average of 26.7 months. The 3-year and 5-year recurrence-free survival rate was 69.4% and 63.1%, respectively. Multivariate analysis showed that the tumor level within the sacrum (P = .001) and the surgical margin (P = .001) were significant recurrence-related factors. Four patients (16.7%) developed lung metastasis. Eighteen patients were alive at last follow-up. The 5-year and 10-year survival rate after surgical treatment of recurrence was 67.3% and 53.9%, respectively. Most recurrent tumors are located in bone, and a safe osteotomy margin is important. The surgical margin is the only controllable factor of further tumor recurrence. Some patients with recurrence achieve long survival and obtain a clinical benefit from repeated operations if complete resection is achieved. Wolters Kluwer Health 2018-12-28 /pmc/articles/PMC6314672/ /pubmed/30593146 http://dx.doi.org/10.1097/MD.0000000000013730 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 |
spellingShingle | Research Article Yang, Yongkun Li, Yuan Liu, Weifeng Xu, Hairong Niu, Xiaohui The clinical outcome of recurrent sacral chordoma with further surgical treatment |
title | The clinical outcome of recurrent sacral chordoma with further surgical treatment |
title_full | The clinical outcome of recurrent sacral chordoma with further surgical treatment |
title_fullStr | The clinical outcome of recurrent sacral chordoma with further surgical treatment |
title_full_unstemmed | The clinical outcome of recurrent sacral chordoma with further surgical treatment |
title_short | The clinical outcome of recurrent sacral chordoma with further surgical treatment |
title_sort | clinical outcome of recurrent sacral chordoma with further surgical treatment |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314672/ https://www.ncbi.nlm.nih.gov/pubmed/30593146 http://dx.doi.org/10.1097/MD.0000000000013730 |
work_keys_str_mv | AT yangyongkun theclinicaloutcomeofrecurrentsacralchordomawithfurthersurgicaltreatment AT liyuan theclinicaloutcomeofrecurrentsacralchordomawithfurthersurgicaltreatment AT liuweifeng theclinicaloutcomeofrecurrentsacralchordomawithfurthersurgicaltreatment AT xuhairong theclinicaloutcomeofrecurrentsacralchordomawithfurthersurgicaltreatment AT niuxiaohui theclinicaloutcomeofrecurrentsacralchordomawithfurthersurgicaltreatment AT yangyongkun clinicaloutcomeofrecurrentsacralchordomawithfurthersurgicaltreatment AT liyuan clinicaloutcomeofrecurrentsacralchordomawithfurthersurgicaltreatment AT liuweifeng clinicaloutcomeofrecurrentsacralchordomawithfurthersurgicaltreatment AT xuhairong clinicaloutcomeofrecurrentsacralchordomawithfurthersurgicaltreatment AT niuxiaohui clinicaloutcomeofrecurrentsacralchordomawithfurthersurgicaltreatment |